Inflammatory Bowel Disease (IBD) Pipeline Analysis Report 2026

Report Coverage

The Inflammatory Bowel Disease (IBD) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into inflammatory bowel disease (IBD) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for inflammatory bowel disease (IBD). The inflammatory bowel disease (IBD) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The inflammatory bowel disease (IBD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with inflammatory bowel disease (IBD) treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to inflammatory bowel disease (IBD).

Read more about this report - Request a Free Sample

Inflammatory Bowel Disease (IBD) Pipeline Outlook

Inflammatory bowel disease (IBD) is a chronic gastrointestinal condition involving persistent inflammation of the digestive tract, mainly including Crohn’s disease and ulcerative colitis. It occurs due to abnormal immune system responses to gut microbiota, influenced by genetic and environmental factors, leading to ongoing intestinal damage, abdominal pain, diarrhea and malabsorption issues.

Inflammatory bowel disease (IBD) treatments include aminosalicylates, corticosteroids, immunosuppressants, biologics, and Janus kinase inhibitors to reduce inflammation, induce remission, and manage Crohn’s disease and ulcerative colitis effectively in clinical practice settings. In May 2026, upadacitinib (Rinvoq), a Janus kinase inhibitor, showed strong outcomes in inflammatory bowel disease pipeline studies, demonstrating rapid response in Crohn’s disease and ulcerative colitis. Oral therapy improves remission rates and supports ongoing clinical trials in advanced JAK inhibitors for IBD management.

Inflammatory Bowel Disease (IBD) Epidemiology

Inflammatory bowel disease (IBD) continues to show a rising clinical burden, driving significant activity in the pipeline. According to Gastroenterology Advisor, more than 0.7% of Americans are expected to develop IBD during their lifetime, with 2.39 million cases in the United States, including 1.25 million ulcerative colitis and 1.01 million Crohn’s disease patients. As per Bénédicte Caron et al., 2024, incidence varies globally from 0.21 to 46.14 per 100,000 population, with higher rates in North America and Europe. Rising epidemiological burden and unmet clinical needs are accelerating pipeline development in advanced biologics and targeted therapies. Overall, expanding prevalence continues to strengthen long-term demand for innovative IBD treatment options.

Inflammatory Bowel Disease (IBD) – Pipeline Therapeutic Assessment

Inflammatory Bowel Disease (IBD) Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II with 41%, covers a major share of the total inflammatory bowel disease (IBD) clinical trials, driven by efficacy validation and strong clinical advancement supporting robust inflammatory bowel disease treatment development. Phase I at 14% focuses on safety profiling. Phase III with 23%, strengthens late-stage efficacy confirmation. Phase IV accounted for 17% enables real-world evidence while early phase I with 5% supports innovation collectively accelerating market growth and therapeutic expansion.

Inflammatory Bowel Disease (IBD) Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the Inflammatory Bowel Disease (IBD) pipeline analysis include small molecules, monoclonal antibodies, and oligonucleotides. The inflammatory bowel disease (IBD) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for inflammatory bowel disease (IBD). Immune-based drug therapies are also emerging to provide effective solutions for the patients. For instance, recently, U.S. FDA accepted Takeda’s application for ENTYVIO (vedolizumab) in pediatric ulcerative colitis and Crohn’s disease, highlighting growth in integrin antagonist’s pipeline. Moreover, JAK inhibitors, IL-23 inhibitors, S1P receptor modulators, and anti-TNF biologics are advancing IBD treatment outcomes.

Inflammatory Bowel Disease (IBD) Clinical Trials – Key Players

The EMR report for the inflammatory bowel disease (IBD) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Inflammatory Bowel Disease (IBD) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in inflammatory bowel disease (IBD) clinical trials:

• Disc Medicine, Inc.
• Morphic Therapeutic, Inc.
• Takeda
• iCell Gene Therapeutics
• Mirador Therapeutics, Inc.
• Shandong Suncadia Medicine Co., Ltd.
• Shanghai Pharmaceuticals Holding Co., Ltd.
• Parvus Therapeutics, Inc.
• Eli Lilly and Company
• Athos Therapeutics Inc.
• Spyre Therapeutics, Inc.
• Intralytix, Inc.

Inflammatory Bowel Disease (IBD) – Emerging Drugs Profile

Key Questions Answered in the Inflammatory Bowel Disease (IBD) Pipeline Insight Report

• Which companies/institutions are leading inflammatory bowel disease (IBD) drug development?
• Which company is leading the inflammatory bowel disease (IBD) pipeline development activities?
• What is the current inflammatory bowel disease (IBD) commercial assessment?
• What are the opportunities and challenges present in the inflammatory bowel disease (IBD) pipeline landscape?
• What is the efficacy and safety profile of inflammatory bowel disease (IBD) pipeline drugs?
• Which company is conducting major trials for inflammatory bowel disease (IBD) drugs?
• Which companies/institutions are involved in inflammatory bowel disease (IBD) collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in inflammatory bowel disease (IBD)?

Reasons To Buy This Report

The Inflammatory Bowel Disease (IBD) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for inflammatory bowel disease (IBD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into inflammatory bowel disease (IBD) collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Inflammatory Bowel Disease Treatment Market

Inflammatory Bowel Disease (IBD) Epidemiology